Published in PLoS One on March 26, 2013
Human and Murine Clonal CD8+ T Cell Expansions Arise during Tuberculosis Because of TCR Selection. PLoS Pathog (2015) 1.44
Antigens for CD4 and CD8 T cells in tuberculosis. Cold Spring Harb Perspect Med (2014) 0.93
Toward Understanding the Essence of Post-Translational Modifications for the Mycobacterium tuberculosis Immunoproteome. Front Immunol (2014) 0.85
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med (2016) 0.83
The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis (Edinb) (2015) 0.82
T-Cell Therapy: Options for Infectious Diseases. Clin Infect Dis (2015) 0.78
Cytotoxic response persists in subjects treated for tuberculosis decades ago. BMC Infect Dis (2013) 0.77
Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32. Ann Transl Med (2015) 0.76
Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa. AIDS Res Hum Retroviruses (2014) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2006) 8.90
Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol (2002) 8.88
Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 7.90
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med (1993) 7.85
Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol (1999) 7.18
Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun (1995) 6.43
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
The immune epitope database 2.0. Nucleic Acids Res (2009) 6.07
Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med (2003) 5.22
HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A (1992) 5.02
Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci U S A (2004) 4.98
Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet (2010) 4.94
A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol (2003) 4.66
Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol (1991) 4.44
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity (2008) 4.25
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69
New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens (2003) 3.30
High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity (1998) 2.49
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol (2008) 2.27
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest (2009) 2.12
Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol (2005) 2.08
Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature (1994) 1.88
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun (2007) 1.85
Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse. J Immunol (2003) 1.84
Antigen bias in T cell cross-priming. Science (2004) 1.82
Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog (2007) 1.78
Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med (1994) 1.74
The effect of phenolic glycolipid-1 from Mycobacterium leprae on the antimicrobial activity of human macrophages. J Exp Med (1988) 1.70
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Increase in gamma interferon-secreting CD8(+), as well as CD4(+), T cells in lungs following aerosol infection with Mycobacterium tuberculosis. Infect Immun (1999) 1.49
Characterization of three glycosyltransferases involved in the biosynthesis of the phenolic glycolipid antigens from the Mycobacterium tuberculosis complex. J Biol Chem (2004) 1.41
Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology (2006) 1.41
Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One (2009) 1.33
The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med (2005) 1.28
Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol (2005) 1.28
Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol (2006) 1.26
Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol (2008) 1.21
A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine (2012) 1.16
Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition. Proc Natl Acad Sci U S A (2010) 1.13
Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun (2005) 1.07
CD4 and CD8 T-cell responses to mycobacterial antigens in African children. Am J Respir Crit Care Med (2010) 1.04
Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health (2011) 1.03
Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun (2007) 1.02
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol (2008) 1.01
Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS One (2008) 1.00
Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Clin Vaccine Immunol (2009) 0.97
MHC class II tetramer guided detection of Mycobacterium tuberculosis-specific CD4+ T cells in peripheral blood from patients with pulmonary tuberculosis. Scand J Immunol (2007) 0.95
Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria. Mol Immunol (2009) 0.87
The biosynthesis of mycolic acids in Mycobacterium tuberculosis. Enzymatic methyl(ene) transfer to acyl carrier protein bound meromycolic acid in vitro. J Biol Chem (1998) 0.87
Definition of the HLA-A2 restricted peptides recognized by human CD8+ effector T cells by flow-assisted sorting of the CD8+ CD45RA+ CD28- T cell subpopulation. Clin Exp Immunol (2003) 0.82
Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition. Clin Vaccine Immunol (2010) 0.81
Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus. BMC Infect Dis (2012) 0.80
Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques (2004) 6.42
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis (2010) 5.14
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet (2009) 4.53
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2009) 4.14
Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol (2008) 3.19
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet (2002) 2.92
Immunological biomarkers of tuberculosis. Nat Rev Immunol (2011) 2.88
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet (2003) 2.64
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med (2009) 2.55
Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis (2012) 2.42
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One (2011) 2.40
Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS (2005) 2.38
Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis (2012) 2.29
Progress towards improved tuberculosis diagnostics for developing countries. Lancet (2006) 2.16
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Direct comparison of the diagnostic yield of ultrasound-assisted Abrams and Tru-Cut needle biopsies for pleural tuberculosis. Thorax (2009) 2.10
An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS One (2008) 2.06
Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 2.05
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One (2010) 2.03
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol (2006) 1.99
Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One (2012) 1.97
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 1.94
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect (2012) 1.84
Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med (2010) 1.73
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol (2005) 1.72
Lung remodeling in pulmonary tuberculosis. J Infect Dis (2005) 1.71
Evaluation of adapted whole-blood interferon-gamma release assays for the diagnosis of pleural tuberculosis. Respiration (2008) 1.71
Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis (2012) 1.69
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med (2014) 1.69
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol (2009) 1.67
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
Reversing the tide of the UK tuberculosis epidemic. Lancet (2013) 1.61
Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med (2009) 1.57
BCG: the story continues. Lancet (2005) 1.55
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 1.50
Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol (2004) 1.48
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine (2009) 1.45
Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet (2003) 1.43
Tuberculosis in the UK--time to regain control. BMJ (2011) 1.43
The Hajj pilgrimage and surveillance for Middle East Respiratory syndrome coronavirus in pilgrims from African countries. Trop Med Int Health (2014) 1.42
Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying of respiratory tract illnesses. J Pediatr (2002) 1.42
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2010) 1.41
Tuberculosis in prisons in sub-Saharan Africa--the need for improved health services, surveillance and control. Tuberculosis (Edinb) (2011) 1.40
New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med (2011) 1.40
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis (2013) 1.39
LifeGene--a large prospective population-based study of global relevance. Eur J Epidemiol (2010) 1.38
Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon. BMC Res Notes (2008) 1.37
A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med (2003) 1.35
Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS One (2009) 1.34
rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One (2008) 1.31
Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta , and interleukin-4 mRNA levels. J Infect Dis (2007) 1.30
Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach. BMC Bioinformatics (2010) 1.30
Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J Immunol Methods (2005) 1.29
Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis (2012) 1.28
Validation of peptide epitope microarray experiments and extraction of quality data. J Immunol Methods (2007) 1.28
The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr (2010) 1.27
Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med (2010) 1.23
Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am (2010) 1.23
Tuberculosis control is crucial to achieve the MDGs. Lancet (2010) 1.22
Role of CCL5 (RANTES) in viral lung disease. J Virol (2006) 1.21
Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med (2014) 1.20
The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Soc Sci Med (2002) 1.19
How great is the risk of Middle East respiratory syndrome coronavirus to the global population? Expert Rev Anti Infect Ther (2013) 1.19
Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J (2013) 1.19
Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine (2009) 1.18
Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS (2012) 1.18
Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis (2007) 1.18
Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin Vaccine Immunol (2010) 1.17
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Progress and challenges in childhood tuberculosis. Lancet Infect Dis (2013) 1.16
Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology (2004) 1.15
Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One (2012) 1.15
Thoracic empyema: current opinions in medical and surgical management. Curr Opin Pulm Med (2010) 1.14
Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect (2008) 1.13
Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health (2010) 1.11
Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One (2012) 1.11
Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health (2010) 1.10